Peregrine Capital Management LLC Acquires New Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Peregrine Capital Management LLC acquired a new stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 86,244 shares of the company's stock, valued at approximately $3,257,000. Peregrine Capital Management LLC owned about 0.07% of Vaxcyte as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Bridgefront Capital LLC grew its stake in shares of Vaxcyte by 4.2% during the 4th quarter. Bridgefront Capital LLC now owns 4,244 shares of the company's stock worth $347,000 after purchasing an additional 172 shares during the period. Smartleaf Asset Management LLC grew its stake in shares of Vaxcyte by 188.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after purchasing an additional 260 shares during the period. Catalyst Funds Management Pty Ltd grew its stake in shares of Vaxcyte by 1.7% during the 4th quarter. Catalyst Funds Management Pty Ltd now owns 18,400 shares of the company's stock worth $1,506,000 after purchasing an additional 300 shares during the period. Avior Wealth Management LLC grew its stake in shares of Vaxcyte by 5.3% during the 1st quarter. Avior Wealth Management LLC now owns 6,799 shares of the company's stock worth $257,000 after purchasing an additional 343 shares during the period. Finally, New York Life Investment Management LLC grew its stake in shares of Vaxcyte by 4.1% during the 4th quarter. New York Life Investment Management LLC now owns 12,469 shares of the company's stock worth $1,021,000 after purchasing an additional 494 shares during the period. 96.78% of the stock is owned by hedge funds and other institutional investors.

Vaxcyte Trading Down 0.1%

PCVX stock traded down $0.04 during midday trading on Friday, reaching $33.24. The stock had a trading volume of 474,884 shares, compared to its average volume of 1,476,699. The company's fifty day simple moving average is $33.32 and its 200 day simple moving average is $57.04. The company has a market cap of $4.29 billion, a price-to-earnings ratio of -8.33 and a beta of 1.19. Vaxcyte, Inc. has a 52-week low of $27.66 and a 52-week high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). During the same quarter in the prior year, the firm posted ($0.85) earnings per share. Sell-side analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on PCVX shares. Guggenheim reaffirmed a "buy" rating and set a $160.00 price objective on shares of Vaxcyte in a research note on Wednesday, March 12th. Bank of America dropped their price target on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Evercore ISI raised shares of Vaxcyte to a "strong-buy" rating in a research note on Monday, March 31st. Cantor Fitzgerald initiated coverage on shares of Vaxcyte in a research note on Tuesday, April 22nd. They issued an "overweight" rating on the stock. Finally, The Goldman Sachs Group dropped their price target on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $136.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.